NASDAQ:ONCE Spark Therapeutics (ONCE) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$113.57▼$113.5750-Day Range$110.05▼$113.5752-Week Range$34.53▼$114.20Volume8,720 shsAverage Volume891,560 shsMarket Capitalization$4.38 billionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Spark Therapeutics (NASDAQ:ONCE) StockSpark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.Read More ONCE Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comGene Therapy Market Size to Reach USD 35.1 Billion By 2032 CAGR: 16.4%. Report By DataHorizzon ResearchSeptember 14, 2023 | news.yahoo.comControversial park sign sparks divided reaction online: ‘I need a couple copies of this sign’October 4, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 12, 2023 | yahoo.com‘Pain Hustlers’ Review: Emily Blunt Dominates Netflix’s Simplistic Opioid DramaSeptember 8, 2023 | benzinga.comEXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System CancersSeptember 5, 2023 | markets.businessinsider.comSernova Corporation Announces the Appointment of Cynthia Pussinen as CEOSeptember 1, 2023 | msn.comFTSE 100 Live: London blue-chips climb amid big GDP revision, surprise jump in US unemploymentAugust 29, 2023 | benzinga.comSpark Biomedical Awarded $1.15M Department of Defense Phase II STTR Grant in Partnership with Battelle Memorial InstituteOctober 4, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.August 16, 2023 | msn.comJim Kenney 1,000 days in: The fine print of the Philly mayor’s promisesAugust 14, 2023 | usatoday.comCapital One Spark Miles Card review 2023July 27, 2023 | bizjournals.comMD Anderson partners with newly financed biotech to target 'undruggable' cancersJuly 14, 2023 | yahoo.comJake Owen Was Asked About Theories That Taylor Swift's 'Sparks Fly' Is About Him...July 14, 2023 | msn.comJake Owen Was Asked About Theories That Taylor Swift's 'Sparks Fly' Is About HimJune 28, 2023 | msn.comCity's plan to remove 3rd Avenue cycle track sparks petition to save itJune 12, 2023 | yahoo.comWatch Sparks perform a frenzied This Town Ain't Big Enough For Both Of Us in 1974June 8, 2023 | thestreet.comCelladon Heart-Failure Study Looms Large as Next Big Test for Gene TherapyJune 7, 2023 | msn.comStorm Oscar risks bringing thunderstorms to Stoke-on-Trent as temperatures to hit 24CJune 1, 2023 | marketwatch.comMonopar Therapeutics Shares Rise 6% After New Data on CamsirubicinJune 1, 2023 | markets.businessinsider.comWhere Monopar Therapeutics Stands With AnalystsMay 29, 2023 | msn.comSparks talk new album, ever-growing fanbase: "Our audiences are pretty accepting of eccentricities"May 23, 2023 | tmcnet.comSpark +AI launches: a new era for Spark arrives with AI-powered email which elevates your writing, and ignites productivityMay 22, 2023 | businessinsider.comMeet Wall Street's rising stars of equity research, the ones to watch as the stock market faces one of its biggest challenges yetMay 9, 2023 | msn.comHow Guilt Made Redfall's Bloody Tom a True MonsterApril 30, 2023 | msn.comSchool is in session as Sparks begin training campApril 27, 2023 | msn.comRecovering the Gains Made in Africa Through Vaccinations [press release]April 22, 2023 | thestreet.com13 Companies to Watch From MIT's Smart 50 List, Including 4 BuysSee More Headlines Receive ONCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spark Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCE Company Calendar Last Earnings8/07/2018Today10/04/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological Products, Except Diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONCE CUSIPN/A CIK1609351 Webwww.sparktx.com Phone888-772-7560FaxN/AEmployees368Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,820,000.00 Net Margins-358.41% Pretax MarginN/A Return on Equity-59.10% Return on Assets-33.13% Debt Debt-to-Equity Ratio0.35 Current Ratio4.67 Quick Ratio4.35 Sales & Book Value Annual Sales$64.72 million Price / Sales67.60 Cash FlowN/A Price / Cash FlowN/A Book Value$13.15 per share Price / Book8.64Miscellaneous Outstanding Shares38,523,000Free FloatN/AMarket Cap$4.38 billion OptionableOptionable Beta2.05 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Jeffrey D. Marrazzo (Age 40)Co-Founder, CEO & Director Dr. Katherine A. High (Age 67)Co-Founder, Pres, Head of R&D and Director Mr. Stephen W. Webster (Age 58)Chief Financial Officer Mr. Joseph W. La Barge Esq. (Age 48)J.D., Chief Legal Officer & Sec. Mr. Daniel R. Faga (Age 39)Chief Bus. Officer Key CompetitorsImmunovantNASDAQ:IMVTHalozyme TherapeuticsNASDAQ:HALOAbcamNASDAQ:ABCMCRISPR TherapeuticsNASDAQ:CRSPGinkgo BioworksNYSE:DNAView All Competitors ONCE Stock - Frequently Asked Questions How were Spark Therapeutics' earnings last quarter? Spark Therapeutics Inc (NASDAQ:ONCE) issued its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.34. The biotechnology company earned $25.19 million during the quarter, compared to the consensus estimate of $29.44 million. Spark Therapeutics had a negative trailing twelve-month return on equity of 59.10% and a negative net margin of 358.41%. What other stocks do shareholders of Spark Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spark Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Brainstorm Cell Therapeutics (BCLI), Alibaba Group (BABA), Gilead Sciences (GILD), AbbVie (ABBV), Exelixis (EXEL), Netflix (NFLX), Pfizer (PFE) and When did Spark Therapeutics IPO? (ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers. What is Spark Therapeutics' stock symbol? Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE." What is Spark Therapeutics' stock price today? One share of ONCE stock can currently be purchased for approximately $113.57. How much money does Spark Therapeutics make? Spark Therapeutics (NASDAQ:ONCE) has a market capitalization of $4.38 billion and generates $64.72 million in revenue each year. The biotechnology company earns $-78,820,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. How many employees does Spark Therapeutics have? The company employs 368 workers across the globe. How can I contact Spark Therapeutics? Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The official website for the company is www.sparktx.com. The biotechnology company can be reached via phone at 888-772-7560 or via email at investor@sparktx.com. This page (NASDAQ:ONCE) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spark Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.